Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

Clinical Study on Track to Complete Accrual in Fourth Quarter 2008

BERKELEY HEIGHTS, N.J., June 24 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.

To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, ... and partner Auxilium Pharmaceuticals, Inc. today announced that the ... the European Medicines Agency (EMA) has adopted a positive ... for the treatment of adult men with Peyronie,s disease ... least 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 2011 Matthew Likens, president and CEO of ... company pioneering aesthetic and medical applications using its therapeutic ... two upcoming healthcare  conferences:-- Tuesday, Nov. 29 at 2:10 ... in New York City, Nov. 29-30, 2011 Location: ...
... 2011  The Board of Directors of BD (Becton, Dickinson and Company) ... 45 cents per common share, an increase of 4 cents per ... will be payable on December 30, 2011 to holders of record ... for fiscal year 2012 would be $1.80 cents per share. ...
Cached Medicine Technology:Ulthera CEO - Matthew Likens - to Present at Two Upcoming Healthcare Conferences 2BD Board Increases Dividend 2
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... December 25, 2014 The report “Stivarga ... focuses on the current treatment landscape, unmet needs, current ... Stivarga is a drug which is used in the ... orally administered and is also prescribed to patients who ... is FDA approved is a multi-kinase inhibitor and it ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... researchers say , , TUESDAY, May 19 (HealthDay News) -- ... on her own health but on the respiratory health ... parents are at an increased risk of asthma if ... head of the department of prevention and health services ...
... Calif., May 19 /PRNewswire/ -- ... for Change Award , for the second ... performance in the health care sector. Kaiser Permanente ... CleanMed 2009, a global conference for environmental leaders ...
... a world where people can participate in sensing ... previously invisible. "Participatory Sensing" allows individuals to identify, ... pollution or the damage to fragile ecosystems using ... like cameras, global positioning systems (GPS), and text ...
... Revenue Increase 30% to $ 1.6 Million - Continued ... 19 International Isotopes Inc. (OTC Bulletin Board: INIS) ... 31, 2009. Revenue for the three-month period ended ... for the same period in 2008, an increase of ...
... Leading Veterinary Care Digital Imaging and Data Management ... 19 Eklin Medical Systems, a leading provider ... and Communications Systems) and practice management software (VIA(R)) ... Juan Thorn as the company,s West Coast ultrasound ...
... of swine flu, and in the absence of a vaccine ... virus is to get people around the world to take ... of Springer,s International Journal of Behavioral Medicine , Johannes ... are three key parameters that convince people to take precautions. ...
Cached Medicine News:Health News:Overweight Moms More Likely to Have Asthmatic Kids 2Health News:Overweight Moms More Likely to Have Asthmatic Kids 3Health News:Kaiser Permanente Wins National Awards for Commitment to Environmental Health 2Health News:Kaiser Permanente Wins National Awards for Commitment to Environmental Health 3Health News:There's a sensor in your pocket 2Health News:International Isotopes Inc. Announces First Quarter 2009 Financial Results 2Health News:International Isotopes Inc. Announces First Quarter 2009 Financial Results 3Health News:International Isotopes Inc. Announces First Quarter 2009 Financial Results 4Health News:International Isotopes Inc. Announces First Quarter 2009 Financial Results 5Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:New infectious diseases -- what's the risk? 2
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
... brings to mind images of test tubes, vials, microscopes ... introduction of the Brady Code Reader 2.0 (CR2), you ... of critical lab tools. Brady Corporation has made bar ... with the introduction of the CR2. It is the ...
Reads single TrakMates tubes instantly, and drops decoded tube number instantly into any Windows application. System includes reader and Windows based software....
... top with powder-coated steel legs. ... Available in hundreds of sizes ... drawers, light fixtures and ionizing ... in custom building to meet ...
Medicine Products: